nifekalant hydrochloride has been researched along with Torsade de Pointes in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, K; Kazusa, K; Nakamura, Y; Sugiyama, A; Watanabe, Y | 1 |
| Abe, A; Ikeda, T; Ishiguro, H; Mera, H; Miwa, Y; Miyakoshi, M; Shimizu, H; Tsukada, T; Yoshino, H; Yusu, S | 1 |
| Hazui, H; Kada, A; Nonogi, H; Ohashi, J; Sase, K; Sawano, H; Ukai, I; Yasuda, S; Yokoyama, H | 1 |
| Nagao, K | 1 |
| Hirayama, A; Kasamaki, Y; Kofune, M; Kunimoto, S; Mano, H; Nagashima, K; Ohkubo, K; Okumura, Y; Sonoda, K; Watanabe, I | 1 |
| Hashimoto, K | 1 |
| Kasanuki, H; Katoh, T; Matsuda, N; Mitamura, H; Ogawa, S; Takano, T | 1 |
| Akutsu, K; Hayashi, M; Katoh, T; Kobayashi, Y; Morita, N; Satoh, N; Takano, T; Tanaka, K; Yamamoto, T; Yodogawa, K | 1 |
| Ajiki, K; Hayami, N; Inaba, H; Kunishima, T; Murakawa, Y; Sugishita, Y; Yamagishi, N; Yamagishi, S | 1 |
1 review(s) available for nifekalant hydrochloride and Torsade de Pointes
| Article | Year |
|---|---|
[Preclinical evaluation of drug induced QT prolongation].
Topics: Animals; Anti-Arrhythmia Agents; Cation Transport Proteins; Drug Design; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Pyrimidinones; Torsades de Pointes | 2003 |
1 trial(s) available for nifekalant hydrochloride and Torsade de Pointes
| Article | Year |
|---|---|
Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiography; Emergency Medical Services; Female; Heart Rate; Humans; Infusions, Intravenous; Injections, Intravenous; Lidocaine; Male; Middle Aged; Pyrimidinones; Tachycardia, Ventricular; Torsades de Pointes; Ventricular Fibrillation | 2009 |
7 other study(ies) available for nifekalant hydrochloride and Torsade de Pointes
| Article | Year |
|---|---|
Effects of pH on nifekalant-induced electrophysiological change assessed in the Langendorff heart model of guinea pigs.
Topics: Acidosis; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Guinea Pigs; Humans; Hydrogen-Ion Concentration; Male; Perfusion; Pyrimidinones; Time Factors; Torsades de Pointes | 2014 |
Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.
Topics: Aged; Anti-Arrhythmia Agents; Defibrillators; Electric Countershock; Electrocardiography; Feasibility Studies; Female; Humans; Japan; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Patient Admission; Pilot Projects; Prospective Studies; Pyrimidinones; Registries; Survival Analysis; Survival Rate; Time Factors; Torsades de Pointes; Treatment Failure; Ventricular Fibrillation | 2010 |
Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm.
Topics: Anti-Arrhythmia Agents; Defibrillators; Electric Countershock; Humans; Out-of-Hospital Cardiac Arrest; Patient Admission; Pyrimidinones; Survival Rate; Tachycardia, Ventricular; Time Factors; Torsades de Pointes; Treatment Failure; Ventricular Fibrillation | 2010 |
Effect of the ATP-sensitive K⁺ channel opener nicorandil in a canine model of proarrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Electrocardiography; KATP Channels; Long QT Syndrome; Nicorandil; Pyrimidinones; Torsades de Pointes; Ventricular Premature Complexes | 2011 |
Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation.
Topics: Aged; Anti-Arrhythmia Agents; Emergency Medical Services; Female; Humans; Male; Marketing; Middle Aged; Pyrimidinones; Torsades de Pointes; Ventricular Fibrillation | 2005 |
Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Female; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Pyrimidinones; Torsades de Pointes | 2007 |
Human atrial natriuretic peptide suppresses torsades de pointes in rabbits.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Calcium Channels, L-Type; Cyclic GMP; Disease Models, Animal; Electrocardiography; Humans; Hydralazine; Male; Methoxamine; Pyrimidinones; Rabbits; Sympathomimetics; Torsades de Pointes; Vasodilator Agents | 2008 |